BDTX
NASDAQ · Biotechnology
Black Diamond Therapeutics I
$2.26
+0.10 (+4.40%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 26.85M | 24.30M | 27.99M |
| Net Income | 2.09M | 2.49M | 2.63M |
| EPS | — | — | — |
| Profit Margin | 7.8% | 10.3% | 9.4% |
| Rev Growth | +10.3% | +9.4% | -7.6% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 36.97M | 36.00M | 39.74M |
| Total Equity | 91.17M | 103.86M | 92.20M |
| D/E Ratio | 0.41 | 0.35 | 0.43 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 3.87M | 3.57M | 4.44M |
| Free Cash Flow | 2.98M | 2.09M | 2.99M |